Onbrez (indacaterol) / Novartis - LARVOL DELTA

Late Breaking Abstract - A Phase III, Randomized, Multicentre, Active controlled study to evaluate Fluticasone Furoate, Umeclidinium and Vilanterol in Uncontrolled Asthma Management (ERS 2026) - "Aims and objectives: To assess efficacy and tolerability of a FDC of Fluticasone Furoate 200 mcg, Umeclidinium 62.5 mcg and Vilanterol 25 mcg compared with FDC of Indacaterol 150 mcg, Glycopyrronium 50 mcg and Mometasone furoate 160 mcg powder for inhalation in bronchial asthma Methods Adults patients with moderate-to-severe uncontrolled asthma were enrolled in the study. The FDC of FF/UME/VI was non-inferior to IND/GLY/MF in improving lung function (trough FEV₁) in uncontrolled asthma. Both treatments were well tolerated."

Clinical • Late-breaking abstract • P3 data • Asthma • Immunology • Respiratory Diseases

Genome-scale CRISPR screening uncovers SRSF6 as a target to sensitize hepatocellular carcinoma to radiotherapy. (PubMed, JHEP Rep) - "SRSF6 is a key regulator of HCC radioresistance through its post-transcriptional control of DNA repair capacity, and represents a novel therapeutic target to sensitize HCC to radiotherapy."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • RAD51

Development and characterization of an Indacaterol/Tiotropium Bromide composite dry powder inhalation formulation for COPD. (PubMed, Pharm Sci Adv) - "The introduction of magnesium stearate effectively addressed challenges of poor flowability and particle aggregation in micronized APIs. The formulation exhibits simple preparation process, excellent stability, and superior in vitro pulmonary drug delivery efficacy, making it a promising therapeutic candidate for COPD treatment."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Ciclesonide/indacaterol-encapsulated liposomes: optimizing corticosteroid-bronchodilator therapy for a more effective approach to asthma management. (PubMed, Int J Pharm) - "In an OVA-induced murine model, the optimized formulation markedly attenuated airway hyperresponsiveness and suppressed the type 2 inflammatory cascade, including upstream epithelial-derived alarmins, downstream inflammatory cytokines and inflammatory cell recruitment. Notably, liposomal encapsulation also provided a potential dose-sparing effect for both compounds, suggesting that efficient pulmonary delivery of ICS/LABA via lipid nanoparticles is a promising asthma management strategy and may be applicable to other respiratory diseases."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Discovery and optimization of diarylsulfone-based dual M3-Antagonists and β2-Agonists (MABAs) as inhaled bronchodilators. (PubMed, Eur J Med Chem) - "We report the discovery and optimization of MABAs by integrating a diarylsulfone scaffold with the hydroxyquinoline moiety of indacaterol 2 to achieve dual M3 and β2 activity...Lead compounds 150 and 160 showed high-affinity and long-lived binding to M3 (Ki: 1.95 nM and 1.75 nM, respectively, at 24 h) and subnanomolar β2-agonist potency, along with excellent (EC50 < 10 nM) smooth muscle relaxant activity in carbachol-stimulated guinea pig trachea rings. Moreover, after intratracheal administration, both compounds exhibited sustained in vivo bronchoprotection for 24 h in the modified Einthoven model of acute bronchoconstriction, with equivalent efficacy to the clinical-stage MABA batefenterol 9. Further development of these compounds is warranted as inhaled bronchodilators."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drug-related pulmonary fibrosis: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System. (PubMed, Medicine (Baltimore)) - "Four cardiovascular system drugs (12.12%) included amiodarone (ROR = 41.92), dronedarone (ROR = 10.25), and simvastatin (ROR = 6.94). Four respiratory system drugs (12.12%) included indacaterol (ROR = 6.87), salmeterol/fluticasone (ROR = 4.30), and olodaterol (ROR = 3.76). Four antipathogenic microbial drugs (12.12%) included nitrofurantoin (ROR = 22.92), sulfasalazine (ROR = 5.69), and hydroxychloroquine (ROR = 3.51). Six other drugs (18.18%) included iodine-131 (ROR = 19.72), calcium carbonate (ROR = 8.59), and tamsulosin (ROR = 7.48)...The 3 drugs associated with the greatest PF risk were amiodarone, bleomycin, and nitrofurantoin. These findings highlight potential pharmacovigilance signals that warrant clinical vigilance and further validation through prospective studies."

Adverse events • Journal • Real-world evidence • Cardiovascular • Cough • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases

Repurposing indacaterol as a novel NETs inhibitor for the treatment of colorectal tumor metastasis. (PubMed, Biochem Pharmacol) - "By effectively blocking NET formation and remodeling the immune microenvironment, IND demonstrates significant anti-metastatic potential. Leveraging its established pharmacological and safety profile, Indacaterol represents a promising candidate for rapid clinical repurposing to target NET-mediated metastasis, particularly in malignancies characterized by systemic inflammation."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CD8 • IFNG • IL2RA

Optimizing dry powder delivery during invasive mechanical ventilation via circuit absolute humidity control. (PubMed, Int J Pharm) - "An enclosed delivery chamber housing a capsule DPI (Breezhaler®; indacaterol 150 µg with lactose carriers) was inserted in-line during expiration and actuated for 15 breaths...Delivery was optimized at intermediate humidity (22 mg/L AH) and reduced at both humidity extremes. These data indicated controllable humidification is critical for translating DPI therapy into mechanically ventilated care."

Journal

Comprehensive impurity profiling and stability assessment of indacaterol maleate integrating LC-MS and in silico genotoxicity. (PubMed, J Pharm Biomed Anal) - "The RP-HPLC-UV assay and related substances methods demonstrated specificity, precision, accuracy, linearity, and robustness, confirming their suitability as stability-indicating methods. Overall, this integrated approach provides a robust framework for impurity profiling, stability assessment, and genotoxic risk evaluation of indacaterol maleate, ensuring regulatory compliance and product quality throughout shelf life."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

Targeted Pulmonary Delivery of Indacaterol/Ciclesonide: Advancing Asthma Therapy Through Liposomal Encapsulation (ATS 2026) - No abstract available

Asthma • Immunology • Respiratory Diseases

Optimizing spray-dried liposomes for pulmonary delivery: impact of lipids composition and of drying parameters using experimental design. (PubMed, Eur J Pharm Biopharm) - "Co-encapsulation of clinically relevant drug combinations (formoterol/budesonide and ciclesonide/indacaterol) produced uniform powders with efficient aerosolization, highlighting the therapeutic potential of these formulations. Collectively, these results establish a robust, scalable, and reproducible approach for designing liposomal DPIs, balancing formulation composition, excipient selection, and process parameters. This study demonstrates that strategic integration of scalable technologies can reconcile structural stability, aerodynamic performance, and manufacturability, paving the way for the industrial translation of liposomal dry powders for targeted pulmonary therapies, including asthma and chronic obstructive pulmonary disease (COPD)."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Identification of Cepharanthine as a Potential Therapy of Acid Sphingomyelinase Deficiency by Reducing Cellular Sphingosylphosphorylcholine. (PubMed, J Inherit Metab Dis) - "Eight compounds, floxuridine, dexamethasone, indacaterol maleate, triethylenethiophosphoramide, cytarabine, doramectin, cepharanthine (CEP), and tetrandrine (TE), were identified to abate the accumulation of SPC in ASMD cells. Additionally, CEP could improve mitochondrial morphology and function, and stimulated lysosome biogenesis by promoting TFEB nuclear translocation in ASMD cells. These results suggest that CEP could potentially be developed as a promising candidate for treating ASMD."

Journal • Frontotemporal Lobar Degeneration • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • TFEB

A UNIQUE CASE OF ASTHMA-COPD AND OBSTRUCTIVE SLEEP APNEA OVERLAP SYNDROME ASSOCIATED WITH RESTLESS LEG SYNDROME AND THROMBOCYTOPENIA (CHEST 2025) - "RLS was diagnosed using the International Restless Leg Syndrome Study Group (IRLSSG) criteria.The patient was started on CPAP, ICS budesonide , glycopyrronium bromide plus indacaterol and Pregabalin . CPAP being the mainstay treatment for OSA along with ICS and LABA for overlap syndrome automatically led to improvement in both RLS and thrombocytopenia. The mortality in COPD patients at ICU settings associated with thrombocytopenia is high, hence the importance of early diagnosis becomes crucial. Also, alleviating RLS greatly impacts the severity of dyspnea and overall well being as seen in this patient."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Movement Disorders • Obesity • Obstructive Sleep Apnea • Pulmonary Emphysema • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder • Thrombocytopenia

A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma. (PubMed, Clin Ther) - "Efficacy and safety of VIL-GLY-FF-MDI were found to be similar to those of IND-GLY-MF-DPI in Indian patients with persistent asthma. Clinical Trial Registry India identifier: CTRI/2024/01/061230."

Journal • P3 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

COPD Treatment with Beta 2-Adrenoreceptor Agonists: Medicinal Perspectives and Recent Advances. (PubMed, Mini Rev Med Chem) - "The current study emphasizes the rational development of lead candidates, including trantinterol, isopropyl, tert-butyl, and heterocyclic ring 2-amino-2-phenylethanol derivatives, 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4- benzoxazine-3(4H)-one derivatives (non-substituted, methyl-substituted, dimethyl-substituted), 5- (2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one analogues, indacaterol analogues, saligenin antedrugs, and saligenin alkoxyalkylphenyl sulfonamide derivatives, accompanied by molecular docking studies.This paper also highlights numerous structure-activity relationship investigations and various novel β2 agonists currently in clinical trials and patents. The present review will significantly aid in fostering the research of COPD."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • ADRB2

Real-world novel adverse drug reactions (ADRs) associated with indacaterol (ERS 2025) - "This study provides new insights into the safety profile of indacaterol, identifying potential ADRs not previously reported in clinical trials. Further research is necessary to confirm these findings."

Adverse drug reaction • Clinical • Real-world • Real-world evidence • Alzheimer's Disease • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Dementia • Glaucoma • Heart Failure • Immunology • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Ventricular Tachycardia

Effectiveness Salmeterol-Fluticasone and Indacaterol on FEV1/FVC Post-Tuberculosis Patient at dr. H. Abdul Moeloek Hospital Lampung Province Indonesia (ERS 2025) - "Salmeterol-fluticasone improves lung function better compared to Indacaterol. Conclusions Salmeterol-fluticasone is effective in improving post-tuberculosis who experience a decreased in FEV1/FVC."

Clinical • Infectious Disease • Respiratory Diseases • Tuberculosis

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD. (PubMed, Pharmacol Res Perspect) - "Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol), long (formoterol, salmeterol), and ultra-long-acting (indacaterol, olodaterol, vilanterol) β2-agonists. Comparison with other β-ligands suggests that affinity and duration could both be improved further. However, given the very wide range of molecular pharmacological properties of β-agonists that are clinically effective and widely used, non-pharmacological properties (physiochemical, patient factors, devices and combination inhaler availability) may be as important in final clinical patient outcomes as the molecular pharmacological properties of the individual β2-agonists themselves."

Clinical • Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Identification of key modules and hub genes for sepsis-induced myopathy using weighted gene co-expression network analysis. (PubMed, Front Genet) - "Additionally, leveraging the Connectivity Map (CMAP) database allowed us to predict six potential pharmacological agents-halcinonide, lomitapide, TG-101348, GSK-690693, loteprednol, and indacaterol-that might serve as therapeutic interventions for SIM. This research advances our understanding of the molecular basis of SIM, presenting new diagnostic biomarkers and potential drug targets. Further studies with larger clinical datasets are warranted to validate these findings and explore the therapeutic potential of the identified drugs."

Journal • Infectious Disease • Inflammation • Myositis • Septic Shock • CXCL10 • IL6 • STAT1

Pathophysiology, clinical manifestation, and treatment of tuberculosis-associated chronic obstructive pulmonary disease: a narrative review. (PubMed, Ewha Med J) - "Treatment generally follows current COPD guidelines, advocating the use of long-acting bronchodilators and the selective application of inhaled corticosteroids. Studies have demonstrated that indacaterol significantly improves lung function and respiratory symptoms, while long-acting muscarinic antagonists have shown survival benefits."

Journal • Review • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Fibrosis • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis

In-silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase. (PubMed, Sci Rep) - "The binding stability of Npr1 and Indacaterol complex was also verified through Principal Component Analysis. The result secured from these computational approaches and techniques established that the drug has the potential to be developed as an anti-candida lead targeting candidiasis."

Journal • Candidiasis

A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England. (PubMed, Health Econ Rev) - "BDP/FOR/GLY MS and HS were a dominant treatment alternative compared with FF/UMEC/VI, both MS and HS, and IND/GLY/MF HS in patients with asthma uncontrolled by ICS/LABA."

HEOR • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying. (PubMed, Int J Pharm) - "These results highlight the importance of advancing in vitro methods to better predict in vivo performance and support the development of more effective inhaled therapies. Overall, this work presents a stable, carrier-free inhalation powder with a novel drug combination that achieves efficient lung deposition and six-month stability."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting β2-adrenoceptor agonist, indacaterol, in human airway epithelial cells. (PubMed, J Pharmacol Exp Ther) - "Functional annotation of carbachol + indacaterol-regulated genes identified gene ontology terms associated with several themes, including inflammation. Interaction between a long-acting β2-adrenoceptor agonist and endogenous acetylcholine could, paradoxically, augment airway inflammation in patients with chronic obstructive pulmonary disease."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases